New drug duo targets Tough-to-Treat ovarian cancer
NCT ID NCT06682572
Summary
This study is testing the safety and effectiveness of two oral drugs, avutometinib and defactinib, given together to Japanese patients with a specific type of recurrent ovarian cancer. The goal is to see if this combination can shrink tumors and control the cancer in patients whose disease has returned after prior chemotherapy. Researchers will closely monitor how patients respond and manage any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, 464-8681, Japan
-
Jikei University Hospital
Minato, Tokyo, 105-0003, Japan
-
Kurume University Hospital
Kurume, Fukuoka, 830-0011, Japan
-
Mie University Hospital
Tsu, Mie-ken, 514-8507, Japan
-
Tohoku University Hospital
Sendai, Miyagi, 980-8574, Japan
Conditions
Explore the condition pages connected to this study.